PAX5 and acute lymphoblastic leukemia: The PAX5-plus novel subgroup of BCP-ALL was described by Bastian et al. to harbor a biallelic PAX5 mutation, p.P80R, as a hotspot with homozygous CDKN2A/B deletions and RAS-activating hotspot mutations as cooperative events, and a tendency for more favorable clinical outcomes was observed [29].